Brief: Aardvark Therapeutics Announces FDA Alignment On Protocol Amendment Expanding Phase 3 Hero Trial Population For Prader-Willi Syndrome
08/10/2025 13:16
Oct 8 (Reuters) - Aardvark Therapeutics Inc AARD.O: AARDVARK THERAPEUTICS ANNOUNCES FDA ALIGNMENT ON PROTOCOL AMENDMENT EXPANDING PHASE 3 HERO TRIAL POPULATION FOR PRADER-WILLI SYNDROME AARDVARK THERAPEUTICS ANNOUNCES FDA ALIGNMENT ON PROTOCOL AMENDMENT EXPANDING PHASE 3 HERO TRIAL POPULATION FOR PRADER-WILLI SYNDROME AARDVARK THERAPEUTICS INC - TRIAL ELIGIBILITY AGE CHANGED FROM 13 TO 10 YEARS AARDVARK THERAPEUTICS INC - TOPLINE DATA READOUT FOR TRIAL EXPECTED IN Q3 2026 Source text: ID:nGNX2wRJCK Further company coverage: AARD.O ((Reuters.Briefs@thomsonreuters.com;))